A leader in the field of interventional cardiology for over 35 years, Dr. Gary S. Roubin is noteworthy for developing the first FDA-approved coronary stent, called the Gianturco-Roubin Flex Stent. Over the course of his distinguished career, he pioneered the practice of carotid stenting and invented the top-selling carotid stent in the United States and the leading EmboShield NAV6 Embolic Protection System. Likewise, he is credited for the development of device technologies and innovative techniques for the treatment of coronary and peripheral atherosclerosis, as well as research in the application of coronary angioplasty and stenting in patients with multi-vessel coronary disease.
Now recognized as an interventional cardiology and vascular consultant with Excision Medical, Inc., Dr. Roubin previously served in several faculty positions at acclaimed universities. To wit, he was chief of interventional cardiology at the University of Alabama at Birmingham, chair of the cardiology department and chief of service at Lenox Hills Hospital in New York, and a faculty member at the Emory University School of Medicine. Notably, Dr. Roubin was a visiting professor at Xiamen University in 2008. Since 2020, he has further served on the executive committee of the CREST2 Trial through the National Institutes of Health, a randomized trial comparing carotid revascularization with medical therapy.
Since the inception of his career, Dr. Roubin has published over 280 papers and 225 abstracts in peer-reviewed journals, as well as edited three textbooks on interventional cardiovascular medicine. Furthermore, he has contributed to 20 textbooks on interventional cardiology and vascular medicine and served as the author of “The First Balloon-Expandable Coronary Stent: An Expedition that Changed Cardiovascular Medicine” in 2015.
To prepare for his career, Dr. Roubin first graduated from the University of Queensland School of Veterinary Science in Australia. He subsequently earned a Doctor of Medicine from the University of Queensland in 1975 and a Doctor of Philosophy in cardiovascular physiology from Sydney University Hospital in 1983. His medical training has consisted of a residency in internal medicine and a fellowship in cardiovascular disease at Royal Prince Alfred Hospital in Sydney, Australia, and an additional fellowship in interventional cardiology at Emory University Hospital. He is certified to practice medicine by the Royal Australasian College of Physicians.
For his success, Dr. Roubin was recently honored by the Society for Cardiac Angiography and Intervention in 2023. He previously received the Lifetime Achievement Award from the ISET International Symposium on Endovascular Therapy in 2018 and an accolade for contributions to medicine and science from the University of Queensland in 2013. Furthermore, for 25 consecutive years, Dr. Roubin was named among the Best Doctors and Best Cardiologists in America.
